The relationship between osteoporotic fracture risk and a surrogate: apparent discrepancies between analyses based on individual patient data and summary statistics

被引:7
作者
Barton, I [1 ]
机构
[1] Procter & Gamble Co, Dept Biometr & Stat Sci, Egham TW20 9NW, Surrey, England
关键词
risedronate; fractures; regression analysis; meta-analysis; clinical trial;
D O I
10.1002/pst.123
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There is debate within the osteoporosis research community about the relationship between the risk of osteoporotic fracture and the surrogate measures of fracture risk. Meta-regression analyses based on summary data have shown a linear relationship between fracture risk and surrogate measures, whereas analyses based oil individual patient data (IPD) have shown a nonlinear relationship. We investigated the association between changes in a surrogate measure of fracture incidence, in this case a bone turnover marker for resorption assessed in the three risedronate phase III clinical programmes, and incident osteoporosis-related fracture risk using regression models based on patient-level and trial-level information. The relationship between osteoporosis-related fracture risk and changes in bone resorption was different when analysed on the basis of IPD than when analysed on the basis of a meta-analytic approach (i.e., meta-regression) using summary data (e.g., treatment effect based oil treatment group estimates). This inconsistency in our findings was consistent with those in the published literature. Meta-regression based on summary statistics at the trial level is not expected to reflect causal relationships between a clinical outcome and surrogate measures. Analyses based oil IPD make possible a more comprehensive analysis since all relevant data on a patient level are available. Copyright (C) 2004 John Wiley Sons Ltd.
引用
收藏
页码:205 / 212
页数:8
相关论文
共 29 条
[1]  
[Anonymous], 1997, AM J MED
[2]   Risk of mortality following clinical fractures [J].
Cauley, JA ;
Thompson, DE ;
Ensrud, KC ;
Scott, JC ;
Black, D .
OSTEOPOROSIS INTERNATIONAL, 2000, 11 (07) :556-561
[3]  
Cooper C, 1999, OSTEOPOROSIS INT, V9, P2
[4]   Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs [J].
Cummings, SR ;
Karpf, DB ;
Harris, F ;
Genant, HK ;
Ensrud, K ;
LaCroix, AZ ;
Black, DM .
AMERICAN JOURNAL OF MEDICINE, 2002, 112 (04) :281-289
[5]   Treatment of postmenopausal osteoporosis [J].
Delmas, PD .
LANCET, 2002, 359 (9322) :2018-2026
[6]   Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate [J].
Eastell, R ;
Barton, I ;
Hannon, RA ;
Chines, A ;
Garnero, P ;
Delmas, PD .
JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (06) :1051-1056
[7]   Secondary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action? [J].
Eastell, R ;
Reid, DM ;
Compston, J ;
Cooper, C ;
Fogelman, I ;
Francis, RM ;
Hay, SM ;
Hosking, DJ ;
Purdie, DW ;
Ralston, SH ;
Reeve, J ;
Russell, RGG ;
Stevenson, JC .
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2001, 94 (11) :575-597
[8]  
*EUR AG EV MED PRO, 2001, EV MED HUM US NOT GU
[9]   Risedronate reverses bone loss in postmenopausal women with low bone mass: Results from a multinational, double-blind, placebo-controlled trial [J].
Fogelman, I ;
Ribot, C ;
Smith, R ;
Ethgen, D ;
Sod, E ;
Reginster, JY .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (05) :1895-1900
[10]   Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis - A randomized controlled trial [J].
Harris, ST ;
Watts, NB ;
Genant, HK ;
McKeever, CD ;
Hangartner, T ;
Keller, M ;
Chesnut, CH ;
Brown, J ;
Eriksen, EF ;
Hoseyni, MS ;
Axelrod, DW ;
Miller, PD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (14) :1344-1352